atrophy

(redirected from postmenopausal vaginal atrophy)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to postmenopausal vaginal atrophy: Urogenital Atrophy
References in periodicals archive ?
The Recommendations for the management of postmenopausal vaginal atrophy are published in the December 2010 edition of Climacteric, and are available at http://www.
The report identifies the key trends shaping and driving the global postmenopausal vaginal atrophy therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders.
GlobalData's analysis indicates that the global postmenopausal vaginal atrophy therapeutics market was worth $1,634.
Summary GlobalData has released its pharma report, "PharmaPoint: Postmenopausal Vaginal Atrophy - Current and Future Players".
To order this report: PharmaPoint: Postmenopausal Vaginal Atrophy - Current and Future Players http://www.
EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022 Summary The urogenital tract, specifically the vagina, urethra, bladder, trigone of the bladder, and pelvic floor muscles, contains estrogen receptors.
1 Sexual inactivity increases symptoms of postmenopausal vaginal atrophy 8 3.
List of Tables Table 1: Sources of Prevalence Data Used in the Epidemiology Forecast 11 Table 2: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, N, Select Years, 2012-2022 16 Table 3: 7MM, Calculated Total Prevalence of Postmenopausal Vaginal Atrophy, By Age, %, 2012-2022 18 Table 4: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, By Age, N, 2012 18 Table 5: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, By Severity, N (Row %), 2012 20
The report provides information on the key drivers and challenges of the Postmenopausal Vaginal Atrophy Therapeutics market.
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Postmenopausal Vaginal Atrophy Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
Analysis of the current and future competition in the seven key countries Postmenopausal Vaginal Atrophy Therapeutics market.
Postmenopausal vaginal atrophy is a chronic and progressive condition characterized by symptoms including vaginal dryness, sexual pain (dyspareunia) and irritation.